TOLUNA
6.4.2022 11:02:14 CEST | Business Wire | Press release
Toluna, the leading consumer insights provider and parent company of Harris Interactive and KuRunData, today announced a joint initiative with Harris Interactive in service of the French Presidential and Legislative elections.
The companies are conducting weekly polling to measure French citizens on their preferred candidates, voting intention, and out-of-polling-station results. Harris Interactive has historically led this polling effort. However, this year, Harris Interactive is officially partnering with its sister company, Toluna, to cover the events. This year’s efforts include over 50 pre-election surveys with over 100,000 people interviewed, as well as 5,000 interviews on election day.
Harris Interactive and Toluna will also partner with leading French TV channel and radio station, M6 and RTL, throughout their coverage of the French elections. Harris Interactive and Toluna experts will first provide estimates of their weekly polling for the first and second rounds of the Presidential election, held Sunday, April 10, 2022, and Sunday, April 24, 2022.
The coverage will be live on M6 and RTL and will also be shared on Toluna and Harris Interactive social media networks from 12:00 PM CEST each election day and continuing throughout the day. The timeline will be as follows:
- 12:00 PM: Initial analysis of voter turnout
- 5:00 PM: Estimates of voter turnout
- 8:00 PM: Initial estimate of Presidential election results
- 8:30 PM onwards: Exclusive insights from “Voting Day” survey fielded by Harris Interactive and Toluna to understand voter motivations and abstentions
- Later in the evening: Refined results in real time
Following the Presidential election, Harris Interactive and Toluna will again work with M6 and RTL to deliver weekly polling for the French Legislative elections on June 12, 2022 and June 19, 2022, providing exclusive analysis and estimations of the French National Assembly’s composition.
The coverage will again feature live on M6 and RTL, available online throughout the evening, as well as on multiple social media channels, including:
- Harris Interactive: harris-interactive.fr / @HarrisInt_FR
- Toluna: tolunacorporate.com / @TolunaCorporate
- M6: groupem6.fr/ @M6, @M6Info, @M6Pro
- RTL: rtl.fr / @RTLFrance
Toluna CEO Frederic-Charles Petit, said: “We are thrilled to bring Toluna and Harris Interactive together to deliver our on-demand, real-time insights as part of this critical initiative in France’s political calendar. This is a great honor, and we look forward to delivering the accurate data the public desires.”
“Citizens today are bombarded with massive amounts of information during the election cycle, and it is essential that they have access to quality data as they evaluate candidates and results. For more than 20 years, Harris Interactive has been proud to deliver some of the most accurate measures of French election results, and we look forward to continuing this tradition in partnership with Toluna,” commented Jean-Daniel Lévy, Senior Vice President of Harris Interactive France and Director of Politics and Opinion Department.
About Toluna
Toluna delivers real-time consumer insights at the speed of the on-demand economy. Harris Interactive simplifies complex decisions with critical consumer intelligence. By fusing Harris’s sector expertise and award-winning research with Toluna’s innovative tools and technology, we strive to push market research toward a better tomorrow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005266/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Plus Pertuzumab Approved in the EU as First New Regimen in More than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer1.9.2026 08:30:00 CEST | Press release
Approval based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years Second approval for Enhertu in the EU in two months Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results fro
Paris Hilton Returns as the Face of KARL LAGERFELD as NOT-KARL Debuts for Fall–Winter 20261.9.2026 08:30:00 CEST | Press release
Following the success of the Maison's Fall-Winter 2025 and Spring-Summer 2026 campaigns, KARL LAGERFELD is delighted to announce the extension of its relationship with global entrepreneur, media personality and cultural icon Paris Hilton, continuing a partnership that has resonated with audiences around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831566835/en/ KARL LAGERFELD - Paris Hilton ©Matt Easton As the face of the Maison through Fall-Winter 2026 and Spring-Summer 2027, Paris Hilton returns for the next chapter of KARL LAGERFELD's From Paris With Love story, continuing to bring her signature confidence, wit and individuality. Photographed for the first time by Matt Easton, the Fall-Winter 2026 campaign introduces a new dimension to the narrative while remaining true to the House's established codes. At the heart of the Fall-Winter 2026 story, two masters of self-reinvention meet. Making his debut is NO
Flashnet Partners with Netmore in Strategic Global Partnership for Smart Street Lighting1.9.2026 08:00:00 CEST | Press release
Collaboration combines carrier-grade LoRaWAN® connectivity with award-winning smart street lighting technology to accelerate smart city transformation Netmore Group, the leading network operator and platform provider for Massive IoT, today announced that Flashnet, a Lucy Group company and global leader in intelligent street lighting solutions, has joined Netmore's Pulse Partner Program. The partnership marks another important milestone in Netmore's growing ecosystem, combining best-in-class connectivity with proven smart infrastructure solutions to accelerate the digital transformation of cities and utilities around the world. Driven by rapid urbanisation, government sustainability mandates, and the accelerating rollout of smart city programs worldwide, smart street lighting is increasingly recognized as the entry point for smart city transformation and one of the fastest-growing segments of the global IoT infrastructure market. As municipalities and utilities continue to modernize cri
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom